Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Accumetrics Teams Up With Big Pharma To Push Platelet Function Testing

This article was originally published in The Gray Sheet

Executive Summary

Test maker Accumetrics joined forces with two drug firms last week to push its approach for identifying patients who may not be benefiting from widely prescribed anti-clotting drug regimens

You may also be interested in...



Debate On Antiplatelet Gene Testing Continues; First Point-Of-Care PMA Filed

Nanosphere submitted a PMA late last month for the first point-of-care assay that could make genotyping a more feasible routine tool to guide antiplatelet therapy

Debate On Antiplatelet Gene Testing Continues; First Point-Of-Care PMA Filed

Nanosphere submitted a PMA late last month for the first point-of-care assay that could make genotyping a more feasible routine tool to guide antiplatelet therapy

Debate On Antiplatelet Gene Testing Continues; First Point-Of-Care Test Filed

The first regulatory application for a point-of-care assay for genotyping patients for response to antiplatelet therapy was submitted at the end of August - if Nanosphere's test is approved, it could make genotyping a more feasible routine tool for guiding therapy for Plavix

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT029124

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel